Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent or Metastatic HNSCC Refractory to Platinum and Cetuximab
NCT02255097Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck & Co. Primary endpoints: Objective Response Rate at 36 months, Objective Response Rate in Strong PD-L1 Positive Participants at 36 months and 2 more. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02255097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255097.